Incannex engages QPS for CannQuit and ReneCann
Pharmaceutical Technology
APRIL 17, 2023
The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. CannQuit-Opioid, named CheWell, combines CBD and an opioid antagonist/agonist in a water-soluble chewable tablet to treat opioid addiction.
Let's personalize your content